Skip to main content
Clinical Trials/NCT05242393
NCT05242393
Recruiting
Not Applicable

The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Observational)

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health1 site in 1 country250 target enrollmentMay 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke, Ischemic
Sponsor
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Enrollment
250
Locations
1
Primary Endpoint
Stroke-related disability assessed by the change in Rivermead Mobility Index from baseline to 14th day after treatment initiation
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

The study is aimed at the investigation of the association of biomarkers of circadian rhythms with sleep characteristics and stroke outcome in acute stroke patients. It is designed as an observational cohort study with the retrospective and prospective longitudinal arms.

Detailed Description

In the retrospective arm of the study, the routinely collected data of patients admitted to the stroke unit with acute ischemic stroke (from 2018 till 2022) will be evaluated. In the prospective longitudinal arm, about 200-250 patients admitted to the Stroke Unit of one participating center will undergo examination including the assessment of medical records, stroke characteristics, sleep characteristics and blood sampling for the evaluation of genetic biomarkers of circadian rhythms within the first 2-3 days after admission.The assessment of stroke severity and functional deficit will be repeated at 10-14 days after stroke. The following associations will be assessed: * the association of genetic biomarkers of circadian rhythms with stroke outcome (the difference in neurological and functional deficit from admission to 14th day after stroke), with stroke characteristics (stroke subtype and neuroimaging stroke parameters) and with sleep characteristics. * the association of sleep characteristics with stroke outcome (the difference in neurological and functional deficit from admission to 14th day after stroke) and with stroke characteristics (stroke subtype and neuroimaging stroke parameters).

Registry
clinicaltrials.gov
Start Date
May 1, 2018
End Date
December 31, 2026
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Responsible Party
Principal Investigator
Principal Investigator

Lyudmila Korostovtseva

Senior Researcher, Department for Hypertension

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Eligibility Criteria

Inclusion Criteria

  • acute (symptom onset to admission \<1 days) ischemic stroke
  • ischemic stroke affecting the branches of anterior cerebral artery, middle cerebral artery and posterior cerebral artery
  • age 18-80 years
  • moderate or severe stroke (National Institutes of Health Stroke Scale, NIHSS\>=5)
  • intravascular stroke treatment with thrombolysis or thrombectomy leading to satisfactory reperfusion (if applicable)
  • informed consent

Exclusion Criteria

  • secondary parenchymal hemorrhage (\>hemorrhage index -2)
  • clinically unstable or life-threatening conditions
  • known progressive neurological diseases
  • known psychiatric diseases
  • concomitant benzodiazepine medication
  • drug or alcohol abuse
  • pregnancy
  • disability to participate in the study
  • congestive heart failure with reduced ejection fraction (\<=45%) or New York Heart Association (NYHA) classification III-IV functional class

Outcomes

Primary Outcomes

Stroke-related disability assessed by the change in Rivermead Mobility Index from baseline to 14th day after treatment initiation

Time Frame: From baseline to 14th day after treatment initiation

a standardized scale used to assess mobility in patients with neurological deficits, a maximum of 15 points is possible; higher scores indicate better mobility performance

Stroke-related disability assessed by the change in modified Rankin scale from baseline to 14th day after treatment initiation

Time Frame: From baseline to 14th day after treatment initiation

values of modified Rankin scale (scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke, from 0 (no symptoms) to 6 (dead) points)

Change in the value of National Institutes of Health Stroke Scale from baseline to 14th day after inclusion

Time Frame: From baseline to 14th day after treatment initiation

National Institutes of Health Stroke Scale (NIHSS) is a tool used to objectively quantify the impairment caused by a stroke, 0-42 scores, higher scores characterize worse impairment

Stroke-related disability assessed by the change in Barthel Index from baseline to 14th day after treatment initiation

Time Frame: From baseline to 14th day after treatment initiation

a common scale used to measure performance in activities of daily living, 0-100 scores, higher scores define better performance

Secondary Outcomes

  • Sleep quality assessed by Pittsburgh Sleep Quality Index(Baseline)
  • Sleepiness assessed by Epworth Sleepiness Scale(Baseline)
  • Insomnia assessed by Insomnia severity index(Baseline)
  • Fatigue assessed by Fatigue severity Scale(Baseline)
  • Chronotype assessed by Morningness-Eveningness Questionnaire(Baseline)

Study Sites (1)

Loading locations...

Similar Trials